Journal of the Pediatric Infectious Diseases Society

Journal

Publication Venue For

  • Initial guidance on use of monoclonal antibody therapy for treatment of coronavirus disease 2019 in children and adolescents.  10:629-634. 2021
  • Policy Statement: Antibiotic stewardship in pediatrics.  10:641-649. 2021
  • Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living with Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.  10:201-204. 2021
  • Multicenter Interim Guidance on Use of Antivirals for Children with Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.  10:34-48. 2021
  • Pancreatitis in Pediatric Patients with COVID-19.  10:57-59. 2021
  • Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.  9:701-715. 2020
  • Multidisciplinary Guidance Regarding the Use of Immunomodulatory Therapies for Acute Coronavirus Disease 2019 in Pediatric Patients.  9:716-737. 2020
  • Update From the Advisory Committee on Immunization Practices.  9:645-649. 2020
  • Association of virologic failure and nonnucleoside reverse transcriptase inhibitor resistance found in antiretroviral-naive children infected with human immunodeficiency virus and given efavirenz-based treatment.  9:261-264. 2020
  • Long-term safety and efficacy of dolutegravir in treatment-experienced adolescents with human immunodeficiency virus infection: Results of the impaact p1093 study.  9:159-165. 2020
  • Rhabdomyolysis and acute renal failure in an adolescent with coronavirus disease 2019.  9:507-509. 2020
  • Update from the Advisory Committee on Immunization Practices.  8:495-500. 2019
  • Patient and treatment characteristics by infecting organism in cerebrospinal fluid shunt infection.  8:235-243. 2019
  • The burden of congenital cytomegalovirus infection: A prospective cohort study of 20 000 infants in Finland.  8:205-212. 2019
  • Update from the Advisory Committee on Immunization Practices.  9:3-5. 2019
  • Temporal trends in co-trimoxazole use among children on antiretroviral therapy and the impact of co-trimoxazole on mortality rates in children without severe immunodeficiency.  8:450-460. 2019
  • Update from the advisory committee on immunization practices.  8:379-383. 2019
  • Update From the Advisory Committee on Immunization Practices.  7:270-274. 2018
  • Update From the Advisory Committee on Immunization Practices.  7:181-187. 2018
  • Update from the advisory committee on immunization practices.  7:93-99. 2018
  • Clinical markers and outcomes of neonates with herpes simplex virus deoxyribonucleic acid persistence in cerebrospinal fluid in disseminated and central nervous system infection.  7:E30-E33. 2018
  • Delayed recurrence of herpes simplex virus infection in the central nervous system after neonatal infection and completion of six months of suppressive therapy.  6:e177-e179. 2017
  • Update from the advisory committee on immunization practices.  6:311-316. 2017
  • Pharmacokinetics of darunavir/ritonavir with etravirine both twice daily in human immunodeficiency virus-infected adolescents and young adults.  6:294-296. 2017
  • Update from the Advisory Committee on immunization practices.  6:111-115. 2017
  • Update from the advisory committee on immunization practices.  5:349-355. 2016
  • Pharmacokinetics of once-daily darunavir/ ritonavir with and without etravirine in human immunodeficiency virus-infected children, adolescents, and young adults.  5:131-137. 2016
  • Update from the advisory committee on immunization practices.  5:101-104. 2016
  • Pharmacokinetics and 48-week safety and efficacy of raltegravir for oral suspension in human immunodeficiency virus type-1-infected children 4 weeks to 2 years of age.  4:e76-e83. 2015
  • A randomized, double-blind, placebo-controlled trial of pleconaril for the treatment of neonates with enterovirus sepsis.  5:53-62. 2015
  • Update from the advisory committee on immunization practices.  5:3-6. 2015
  • Outcomes and treatment of chronic methicillin-resistant Staphylococcus aureus differs by staphylococcal cassette chromosome mec (SCCmec) type in children with cystic fibrosis.  4:225-231. 2015
  • Update from the advisory committee on immunization practices.  4:94-95. 2015
  • Update from the advisory committee on immunization practices.  3:282-285. 2014
  • Update from the advisory committee on immunization practices.  3:94-97. 2014
  • Mother-to-child transmission of herpes simplex virus.  3. 2014
  • Update from the advisory committee on immunization practices.  3:1-3. 2014
  • Executive summary: Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: Recommendations from the national institutes of health, the centers for disease control and prevention, the HIV medicine association of the infectious diseases society of America, the pediatric infectious diseases society, and the American academy of pediatrics.  2:293-308. 2013
  • Update from the advisory committee on immunization practices.  2:309-311. 2013
  • Acyclovir dosing in the neonatal period and beyond.  2:179-182. 2013
  • Update from the advisory committee on immunization practices.  2:97-99. 2013
  • International Standard Serial Number (issn)

  • 2048-7193
  • Electronic International Standard Serial Number (eissn)

  • 2048-7207